GlassScriptPhysician profile
Satyasagar Morisetty
NPI 1699771527
$4,794.02
in general payments reported to CMS, 2019-2025
32 companies · $305 in 2025
The $305 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,316 · 2020: $1,029 · 2021: $526 · 2022: $155 · 2023: $444 · 2024: $19.98 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $584 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.92 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,265.00 | 2019-2023 | Breztri |
| Glaxosmithkline, LLC. | $679.40 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Jazz Pharmaceuticals INC. | $672.52 | 2019-2024 | Xywav |
| Grifols USA, LLC | $351.74 | 2019-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $277.17 | 2019-2020 | |
| Insmed, INC. | $242.17 | 2019-2025 | Brinsupri, Arikayce |
| Harmony Biosciences LLC | $178.84 | 2021-2023 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.87 | 2019-2023 | Ofev |
| Actelion Pharmaceuticals US, INC. | $146.37 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $98.44 | 2019 | |
| Resmed Corp | $81.13 | 2019 | |
| Gilead Sciences, INC. | $79.92 | 2019 | |
| Genentech USA, INC. | $62.09 | 2019 | |
| Ani Pharmaceuticals, INC. | $53.50 | 2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $50.00 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $46.77 | 2019 | |
| Verona Pharma, INC. | $39.96 | 2025 | Ohtuvayre |
| Allergan, INC. | $37.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.58 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $24.61 | 2019 | |
| United Therapeutics Corporation | $23.50 | 2020-2021 | |
| Amgen INC. | $22.40 | 2025 | Tezspire |
| Philips North America LLC | $22.02 | 2019 | |
| Covis Pharma Gmbh | $20.90 | 2023 | |
| Genzyme Corporation | $20.36 | 2019 | |
| Circassia INC. | $16.73 | 2020 | |
| Mallinckrodt Enterprises LLC | $15.91 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.23 | 2019 | |
| Novo Nordisk INC | $15.07 | 2021 | |
| Shire North American Group INC | $13.64 | 2019 | |
| Abbvie INC. | $13.41 | 2023 | |
| Axsome Therapeutics, INC. | $12.98 | 2023 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satyasagar Morisetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.